Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 892.10
- Piotroski Score 3.00
- Grade N/A
- Symbol (DRUG)
- Company Bright Minds Biosciences Inc.
- Price $38.24
- Changes Percentage (-13.31%)
- Change -$5.87
- Day Low $36.37
- Day High $44.50
- Year High $79.02
Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/27/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Buy
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.98
- Trailing P/E Ratio -1.14
- Forward P/E Ratio -1.14
- P/E Growth -1.14
- Net Income $-7,372,225
Income Statement
Quarterly
Annual
Latest News of DRUG
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
ViiV Healthcare shares results from trial of Dovato and three-drug therapy for HIV
ViiV Healthcare presented results from the DOLCE trial, showing Dovato's efficacy in treating advanced HIV comparable to a three-drug therapy. The study demonstrated similar viral suppression rates an...
By Yahoo! Finance | 9 hours ago -
Novo Nordisk Stock Has Been Slammed. How a New Weight-Loss Drug Could Boost Shares by 10%.
Novo Nordisk is developing a promising obesity drug that may outperform existing options. Results of a clinical trial are anticipated in December, potentially boosting Novo's shares....
By MarketWatch | 1 day ago -
Al Roker Says He's 'Not Gonna Judge Anybody' Taking Weight Loss Drugs: 'It's Unlike Any Other Addiction'
Al Roker, a TV personality, shares his weight loss journey and supports different paths to health. He emphasizes understanding and non-judgment towards those using weight loss medications. Roker advoc...
By PEOPLE.com | 1 day ago
